Millington Financial Advisors LLC Acquires New Shares of Novo Nordisk A/S (NYSE:NVO)

Financial Advisors

Millington Financial Advisors LLC acquired a new stake in Novo Nordisk A/S (NYSE: NVO – Get Rating) in the fourth quarter, according to its latest filings with the SEC. The fund acquired 6,544 shares of the company stock valued at approximately $886,000.

Many other hedge funds and other institutional investors have also recently changed their stock positions. Schubert & Co increased its stake in Novo Nordisk A/S by 96.2% in the fourth quarter. Schubert & Co now owns 204 shares of the company worth $28,000 after acquiring another 100 shares during the previous quarter. RFP Financial Group LLC purchased a new position in Novo Nordisk A/S for approximately $30,000 in the fourth quarter. Tsfg LLC purchased a new position in Novo Nordisk A/S for approximately $30,000 in the fourth quarter. Worth Asset Management LLC purchased a new position in Novo Nordisk A/S for approximately $32,000 in the first quarter. Finally, Financial Management Professionals Inc. increased its stake in Novo Nordisk A/S by 95.0% in the third quarter. Financial Management Professionals Inc. now owns 312 shares of the company worth $31,000 after acquiring an additional 152 shares during the previous quarter. 6.09% of the shares are currently owned by institutional investors.

Novo Nordisk A/S Turnover 1.4 %

NVO rose $2.30 to $162.73 on Friday. His 599,851 shares in the company were exchanged, but the average trading volume was 1,425,860 shares for him. The company has a 50-day simple moving average of $155.06 and a 200-day simple moving average of $137.19. The company has an equity ratio of 0.29, a quick ratio of 0.69 and a current ratio of 0.89. Novo Nordisk A/S has a 12-month low of $95.02 and a 12-month high of $172.97. The stock has a market cap of $368.25 billion, a PE ratio of 46.23, a price/earnings ratio of 1.67, and a beta of 0.48.

Novo Nordisk A/S (NYSE:NVO – Get Rating) last reported quarterly results on Wednesday, February 1. The company reported his earnings per share (EPS) of $0.83 for the quarter, beating consensus expectations of his $0.81 by $0.02. Novo Nordisk A/S had a return on equity of 73.39% and a net profit margin of 31.44%. The business had $6.6 billion in revenue for the quarter, compared to analyst estimates of $6.74 billion. Sell-side analysts expect his earnings per share for Novo Nordisk A/S this year to be 4.84.

Wall Street Analyst Predicts Growth

NVOs have been the subject of many research reports. Credit Suisse Group upgraded Novo Nordisk A/S’s rating from ‘Neutral’ to ‘Outperforming’ in its report on Thursday 13 April. began covering Novo Nordisk A/S in an investigative report on Thursday, March 16th. They gave the stock a “strong buy” rating: one of his stock research analysts gave the company’s stock a sell rating, three gave it a hold rating, and six gave it a buy rating. ratings, and one gave a strong buy rating. According to MarketBeat, the stock has an average rating of “moderate buy” and a consensus target price of $657.14.

About Novo Nordisk A/S

(get rating)

Novo Nordisk A/S is a global healthcare company engaged in the discovery, development, manufacturing and marketing of pharmaceuticals. It operates through Diabetes and Obesity Care, and Biopharmaceutical segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OADs), obesity, and other serious chronic diseases.

Featured Stories

Quarterly Institutional Ownership of Novo Nordisk A/S (NYSE:NVO)

This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to

Listen to this before considering Novo Nordisk A/S.

MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat has identified five stocks top analysts are quietly whispering to their clients to buy now before the broader market catches on…and Novo Nordisk A/S is on the list. There was no.

Novo Nordisk A/S currently holds a ‘moderate buy’ rating among analysts, although the top rated analysts believe these five stocks are better buys.

See 5 stocks here

A Guide to High and Short Yield Stock Cover

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *